Related Experiment Video
Updated: Feb 15, 2026

Developing a Rat Model for Bipolar Disorder
Published on: May 2, 2025
Brain Age in Bipolar Disorder: Impact of Model Selection and Clinical Factors
Natasha Topolski1, Ercole J Barsotti2, Andrea Boscutti3
1Translational Psychiatry Program, Faillace Department of Psychiatry and Behavioral Sciences, McGovern Medical School, UTHealth, Houston, Texas; Center of Excellence in Mood Disorders, Faillace Department of Psychiatry and Behavioral Sciences, McGovern Medical School, UTHealth, Houston, Texas; Neuroscience Graduate Program, University of Texas M.D. Anderson Cancer Center, UTHealth Graduate School of Biomedical Sciences, Houston, Texas.
Background:
Bipolar disorder (BD) has been associated with accelerated aging, but studies investigating brain age have yielded mixed results. This may reflect differences in methodology and model sensitivity.
Methods:
We compared 3 publicly available brain age models (ENIGMA [Enhancing Neuro Imaging Genetics through Meta Analysis], PyBrainAge, Pyment) using T1-weighted magnetic resonance imaging (MRI) scans from 352 individuals with BD type I and 327 control participants across 4 sites. Predicted age difference (PAD) was calculated as brain age minus chronological age. We examined group differences, medication effects, and age-related patterns using linear mixed-effects models controlling for chronological age, sex, and scanner.
Results:
PAD was higher in participants with BD than in control participants across all models (PyBrainAge: +3.03 years; ENIGMA: +2.78 years; Pyment: +1.43 years; Cohen's d = 0.26-0.36; all ps < .001), with group differences being more pronounced in participants ≥40 years of age. In region-based models, thalamic and ventricular volumes contributed most consistently to elevated PAD in BD. Across all models, lithium-treated participants with BD showed no significant PAD elevation compared with control participants (all ps > .5), while non-lithium-treated participants exhibited significant elevation (+1.47 to 3.24 years; all ps < .01). Within participants with BD, mixed modeling of any current medication status, lithium treatment, and illness duration/severity measures showed that any current medication status was associated with increased PAD (+2.03 to 4.48 years; all ps < .05), whereas lithium use was associated with a 1.87- to 3.67-year reduction in PAD (all ps < .05), and no associations were found with duration/severity metrics.
Conclusions:
Our findings support the presence of elevated brain age in BD and lithium's suggested neuroprotective profile and highlight the influence of the brain age model, MRI scanner, and other confounders on predictions.
Related Concept Videos
Bipolar Disorder
Bipolar Junction Transistor
Impact of Groups on Groups
Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Aging
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
Intrinsically Disordered Proteins

